BMRN — BIOMARIN PHARMACEUTICAL INC

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1048477 ·
Last close
$58.51
Market Cap
$11.33B
52W High
$70.98
52W Low
$49.26
ADV30
2,447,910
Next earnings
2026-11-02

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 1,024,646,000 819,230,000 205,647,000 -122,831,000 11,569,231,000 736,007,000 5,313,199,000
Jun 2026 989,708,000 786,913,000 110,969,000 44,762,000 11,723,442,000 874,005,000 5,401,750,000
Mar 2026 766,208,000 571,209,000 129,630,000 105,527,000 8,591,016,000 2,222,435,000 2,378,909,000
Dec 2025 874,565,000 598,856,000 -44,603,000 -46,573,000 7,594,022,000 1,311,679,000 1,507,023,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$676,618,000
Investing CF
$-4,725,698,000
Financing CF
$3,535,877,000
CapEx
$-122,313,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.10
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$181,664,000
Inventory
$1,796,069,000
Receivables
$1,076,355,000
ST Investments
$0
EBIT TTM
$180,324,000
Pretax Income TTM
$43,665,000
Interest Exp TTM
$136,659,000
Analysts
27

Yahoo Snapshot (yfinance, live)

Total Revenue
$3,655,127,040
EBITDA
$854,987,008
Free Cash Flow
$-16,042,000
Enterprise Value
$14,306,919,424
Total Cash
$736,006,976
Total Debt
$4,190,210,048
Shares Out
193,694,734
Trailing EPS
$-0.10
Book Value
$32.30
ROE
-0.3%
ROA
3.9%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 3,221,253,000 409,495,000 348,901,000 7,594,022,000 1,507,023,000 6,086,999,000 827,994,000
Dec 2024 2,853,915,000 474,239,000 426,859,000 6,988,940,000 1,330,950,000 5,657,990,000 572,841,000
Dec 2023 2,419,226,000 185,780,000 167,645,000 6,841,603,000 1,890,054,000 4,951,549,000 159,259,000
Dec 2022 2,096,039,000 57,410,000 141,561,000 6,375,074,000 1,771,918,000 4,603,156,000 175,902,000

TTM Snapshot

Revenues TTM
$3,406,614,000
NetIncome TTM
$72,972,000
OpCashFlow TTM
—
Assets (Latest)
$11,723,442,000
Forward EPS
$6.37

Max Pain — expiry 2026-12-18

max pain strike: $60.00 · spot: $61.43 · call oi: 3,691 · put oi: 1,706

Peers — same industry

TickerNameMarket CapLastDaily %
RDY DR REDDYS LABORATORIES LTD $12.32B $14.79 —
ELAN Elanco Animal Health Inc $12.92B $25.85 —
MDGL MADRIGAL PHARMACEUTICALS, INC. $9.80B $421.99 —
TGTX TG THERAPEUTICS, INC. $9.48B $62.71 —
SYRE Spyre Therapeutics, Inc. $8.91B $93.81 —

News headlines (Yahoo Finance, 1h cache)

BioMarin Pharmaceutical Bets on Amicus Growth as VOXZOGO Competition Concerns Mount
2026-11-19 12:14 · Yahoo
How Investors Are Reacting To BioMarin (BMRN) Acquired Drug Growth Prospects
2026-11-18 23:18 · Yahoo
BioMarin Pharmaceutical Sees $2.6 Billion Sales Potential in Amicus Drugs as VOXZOGO Expansion Looms
2026-11-16 13:12 · Yahoo
BioMarin Pharmaceutical Hits $1 Billion Revenue Milestone, Advances Rare-Disease Pipeline
2026-11-12 01:12 · Yahoo
BioMarin to Participate in Upcoming Investor Conferences
2026-11-04 14:00 · Yahoo
BioMarin Pharmaceutical Inc (BMRN) Q3 2026 Earnings Call Highlights: First $1 Billion Revenue ...
2026-11-04 03:02 · Yahoo
BioMarin Pharmaceutical Inc. Q3 2026 Earnings Call Summary
2026-11-03 13:30 · Yahoo
BioMarin Beats Q3 Revenue Forecasts but Cuts 2026 Outlook on Voxzogo Timing and Deal Costs
2026-11-03 11:19 · Yahoo
BioMarin (BMRN) Q3 2026 Earnings Call Transcript
2026-11-03 04:43 · Yahoo
BioMarin Pharmaceutical Q3 Earnings Call Highlights
2026-11-03 02:14 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.